Description:

Imicarb® Injection manufacturer is SavaVet. Imicarb® Injection comprises the active ingredient called Imidocarb – a carbanilide derivative with antiprotozoal activity.

Indications:

treatment and prevention of canine babesiosis (a malaria-like parasitic disease caused by infection with Babesia);

treatment of canine ehrlichiosis (tick-borne disease caused by infection with bacteria of the genus Ehrlichia).

Tick-borne diseases have a tendency to cause cross-infection and Imicarb® may be capable of fighting both canine ehrlichiosis and babesiosis simultaneously.

MOA (mechanism of action):

Imidocarb appears to act directly on the parasite, causing the alteration in number and size of nuclei and in morphology (vacuolation) of the cytoplasm. The antiprotozoal activity is derived from the carbanilide acting on glycolysis of the parasite.

Dosage

Imicarb® is suitable for intramuscular (IM) or subcutaneous injection.

Intramuscular or subcutaneous: 0,5-1,0 ml per 10 kg of body weight.

Imicarb® is usually given in the form of two injections, two weeks apart.

This drug should not be given intravenously (IV), and it should be noted that it can cause burns to the skin.

Precautions:

Keep the injection site and needle free from the residue of Imicarb®.

Imicarb® injection can be given instead of tetracycline or in conjunction with Doxycycline.

Imicarb® should only be given as a secondary alternative to Tetracycline or Doxycycline.

Description:

Imicarb® Injection manufacturer is SavaVet. Imicarb® Injection comprises the active ingredient called Imidocarb – a carbanilide derivative with antiprotozoal activity.

Indications:

treatment and prevention of canine babesiosis (a malaria-like parasitic disease caused by infection with Babesia);

treatment of canine ehrlichiosis (tick-borne disease caused by infection with bacteria of the genus Ehrlichia).

Tick-borne diseases have a tendency to cause cross-infection and Imicarb® may be capable of fighting both canine ehrlichiosis and babesiosis simultaneously.

MOA (mechanism of action):

Imidocarb appears to act directly on the parasite, causing the alteration in number and size of nuclei and in morphology (vacuolation) of the cytoplasm. The antiprotozoal activity is derived from the carbanilide acting on glycolysis of the parasite.

Dosage

Imicarb® is suitable for intramuscular (IM) or subcutaneous injection.

Intramuscular or subcutaneous: 0,5-1,0 ml per 10 kg of body weight.

Imicarb® is usually given in the form of two injections, two weeks apart.

This drug should not be given intravenously (IV), and it should be noted that it can cause burns to the skin.

Precautions:

Keep the injection site and needle free from the residue of Imicarb®.

Imicarb® injection can be given instead of tetracycline or in conjunction with Doxycycline.

Imicarb® should only be given as a secondary alternative to Tetracycline or Doxycycline.